Oral Paltusotine for Acromegaly Treatment
Author Information
Author(s): Mônica R. Gadelha, Alessandra Casagrande, Christian J. Strasburger, Martin Bidlingmaier, Peter J. Snyder, Mirtha A. Guitelman, Cesar L. Boguszewski, Michael Buchfelder, Ilan Shimon, Gerald Raverot, Miklós Tóth, Emese Mezősi, Mirjana Doknic, Xiaolin Fan, David Clemmons, Peter J. Trainer, R. Scott Struthers, Alan Krasner, Beverly M. K. Biller
Primary Institution: Crinetics Pharmaceuticals, Inc.
Hypothesis
Can switching from injected somatostatin receptor ligands to oral paltusotine maintain disease control in acromegaly patients?
Conclusion
Oral paltusotine effectively maintained biochemical and symptom control in acromegaly patients previously treated with injected somatostatin receptor ligands.
Supporting Evidence
- 83.3% of patients on paltusotine maintained IGF-I ≤1.0× ULN compared to 3.6% on placebo.
- Paltusotine showed significant improvement in IGF-I levels and acromegaly symptoms compared to placebo.
- Lower rates of rescue medication use were observed in the paltusotine group (6.7%) compared to placebo (60.7%).
- Patients reported a significant reduction in acromegaly symptoms when treated with paltusotine.
Takeaway
This study shows that taking a pill called paltusotine can help people with acromegaly feel better and keep their hormone levels normal, just like getting shots.
Methodology
This was a phase 3, randomized, double-blind, placebo-controlled trial with patients switched from injected somatostatin receptor ligands to oral paltusotine for 36 weeks.
Limitations
The study only included patients with controlled acromegaly on injected SRLs, which may not represent all acromegaly patients.
Participant Demographics
{"age_mean":55.9,"sex_distribution":{"female":50,"male":50},"race_distribution":{"white":76.7,"black_or_african_american":6.7,"asian":0,"multiple_or_other":10.0,"unknown":6.7},"ethnicity":{"his":36.7,"not_his":56.7,"unknown":6.7}}
Statistical Information
Confidence Interval
95% CI, 13.73->999.99
Statistical Significance
p<0.0001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website